Key result
Ablation of IL-17A signaling protected mice from post-infarct heart failure and death, improving 28-day survival to 88% compared to 50% in wild-type mice.
Answers are grounded in this paper and cite their sources.
Identifies a specialized, plastic subset of cardiac fibroblasts that drives heart failure via IL-17A-induced GM-CSF production, presenting a potential therapeutic target.
The causative effect of GM‐CSF produced by cardiac fibroblasts to development of heart failure has not been shown. We identified the pathological GM‐CSF‐producing cardiac fibroblast subset and the specific deletion of IL‐17A signaling to these cells attenuated cardiac inflammation and heart failure. We describe here the CD45 − CD31 − CD29 + mEF‐SK4 + PDGFRα + Sca‐1 + periostin + (Sca‐1 + ) cardiac fibroblast subset as the main GM‐CSF producer in both experimental autoimmune myocarditis and myocardial infarction mouse models. Specific ablation of IL‐17A signaling to Sca‐1 + periostin + cardiac fibroblasts ( Postn Cre Il17ra fl/fl ) protected mice from post‐infarct heart failure and death. Moreover, Postn Cre Il17ra fl/fl mice had significantly fewer GM‐CSF‐producing Sca‐1 + cardiac fibroblasts and inflammatory Ly6C hi monocytes in the heart. Sca‐1 + cardiac fibroblasts were not only potent GM‐CSF producers, but also exhibited plasticity and switched their cytokine production profiles depending on local microenvironments. Moreover, we also found GM‐CSF‐positive cardiac fibroblasts in cardiac biopsy samples from heart failure patients of myocarditis or ischemic origin. Thus, this is the first identification of a pathological GM‐CSF‐producing cardiac fibroblast subset in human and mice hearts with myocarditis and ischemic cardiomyopathy. Sca‐1 + cardiac fibroblasts direct the type of immune cells infiltrating the heart during cardiac inflammation and drive the development of heart failure.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2018) studied Heart failure (myocarditis and myocardial infarction). IL-17A signaling ablation (Il17ra-/- or Postn Cre Il17ra fl/fl) vs. Wild-type controls was evaluated on 28-day survival post-myocardial infarction. Ablation of IL-17A signaling protected mice from post-infarct heart failure and death, improving 28-day survival to 88% compared to 50% in wild-type mice.
Synapse has enriched 10 related papers. Consider them for comparative context: